IN VITRO MODELS FOR EVALUATION

用于评估的体外模型

• 批准号: 2308736
• 负责人: CHARLES E RUEGG
• 金额: $ 4.99万
• 依托单位: IN VITRO TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-06-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2308736
• 关键词: VITRO; MODELS; EVALUATION

The long term objective is to establish and validate in vitro systems for detecting and studying peroxisomal proliferators (PP), and to the hazard of these chemicals to human health. The specific aims of Phase I are to establish and evaluate the reliability of in vitro systems including (1) rat primary hepatocyte culture, (2) rat liver slice culture, and (3) human hepatocyte and/or slice culture. These in vitro systems will be evaluated using chemicals known to induce PP and other chemicals which do not induce PP, and specific indicators of the PP response will be measured. These indicators include (1) altered ratios of intracellular beta-oxidation:catalase activity, (2) increased DNA synthesis, and (3) altered cell morphology. The results of these studies should provide information about the reliability, accuracy, and sensitivity of these systems for detecting and studying mechanisms of PP. In Phase II a wide variety of PP-inducing chemicals will be studied in both rodent and human in vitro systems to better define the hazard of these chemicals to human health. The commercial availability of an in vitro system for evaluating PP will significantly benefit companies who wish to evaluate the PP-inducing potential and health hazard of their products.

长期目标是建立和验证体外系统 检测和研究过氧化物酶体增生剂（PP），并针对危险 这些化学物质对人类健康。 第一阶段的具体目的是 建立和评估体外系统的可靠性，包括（1） 大鼠原发性肝细胞培养，（2）大鼠肝切片培养和（3）人类 肝细胞和/或切片培养。 这些体外系统将使用已知诱导的化学物质进行评估 PP和其他不诱导PP的化学品，以及 将测量PP响应。 这些指标包括（1）已更改 细胞内β-氧化的比率：过氧化氢酶活性，（2）DNA增加 合成，（3）细胞形态改变。 这些研究的结果 应提供有关可靠性，准确性和敏感性的信息 这些系统用于检测和研究PP的机制。 在第二阶段 在啮齿动物和 人体体外系统，以更好地定义这些化学物质的危害 人类健康。 用于体外系统的商业可用性 评估PP将对希望评估的公司有益于 PP引起其产品的潜力和健康危害。